이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biosynex 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Larry Abensur

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	9.3yrs
CEO 소유권	6.2%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	9.3yrs

최근 관리 업데이트

Recent updates

CEO

Larry Abensur

9.3yrs

테뉴어

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Larry Abensur	Chairman & CEO	9.3yrs	데이터 없음	6.2% € 2.8m
Thierry Paper	Deputy CEO & Director	9.3yrs	€96.00k	0.99% € 444.7k
Thomas Lamy	Deputy CEO & Director	9.3yrs	데이터 없음	1.56% € 698.8k
Felix Agbalika	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Emmanuel Drouet	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Denis Gallot	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Vincent Sapin	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marc Noizet	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Elie Fraenckel	Director	no data	데이터 없음	데이터 없음

9.3yrs

평균 재임 기간

경험이 풍부한 이사회: 0DL 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.

Biosynex 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

New minor risk - Shareholder dilution

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 24%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Full year 2020 earnings released: EPS €3.43 (vs €0.12 in FY 2019)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

CEO

테뉴어

이사회 구성원

평균 재임 기간